These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30738054)

  • 1. Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment.
    Takeshita J; Eriksen WT; Raziano VT; Bocage C; Hur L; Shah RV; Gelfand JM; Barg FK
    J Invest Dermatol; 2019 Aug; 139(8):1672-1679.e1. PubMed ID: 30738054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
    Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
    J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study.
    Christophers E; Segaert S; Milligan G; Molta CT; Boggs R
    J Dermatolog Treat; 2013 Jun; 24(3):193-8. PubMed ID: 22620684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use.
    Takeshita J; Gelfand JM; Li P; Pinto L; Yu X; Rao P; Viswanathan HN; Doshi JA
    J Invest Dermatol; 2015 Dec; 135(12):2955-2963. PubMed ID: 26214380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Strober B; Gooderham M; de Jong EMGJ; Kimball AB; Langley RG; Lakdawala N; Goyal K; Lawson F; Langholff W; Hopkins L; Fakharzadeh S; Srivastava B; Menter A
    J Am Acad Dermatol; 2018 Jan; 78(1):70-80. PubMed ID: 29102053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
    Busard CI; Cohen AD; Wolf P; Gkalpakiotis S; Cazzaniga S; Stern RS; Hutten BA; Feldhamer I; Quehenberger F; Lichem R; Kojanova M; Adenubiova E; Addis A; Naldi L; Spuls PI
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting.
    Gulliver WP; Randell S; Gulliver S; Gregory V; Nagle S; Chambenoit O
    J Cutan Med Surg; 2018; 22(6):567-576. PubMed ID: 29952225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.
    Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.
    Ighani A; Yu AM; Sandhu VK; Barankin B; Manolson MF
    J Cutan Med Surg; 2019; 23(2):148-156. PubMed ID: 30801221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents.
    Ighani A; Partridge ACR; Shear NH; Lynde C; Gulliver WP; Sibbald C; Fleming P
    J Cutan Med Surg; 2019; 23(2):204-221. PubMed ID: 30463416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study.
    Gleeson D; Naveed M; Moorhead L; McAteer H; Sewell G; McGuire A; Weinman J; Barker JNWN; Norton S; Chapman SCE; Smith CH; Mahil SK
    Br J Dermatol; 2024 Jul; 191(2):243-251. PubMed ID: 38366988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No Racial Differences Found in Access to Biologics: A Population-Based Study of Psoriasis Patients in the United States.
    Reddy R; Khan S; Yee D; Maynard N; Mehta M; Zagona-Prizio C; Khan S; Chat V; Wu K; Armstrong AW
    J Drugs Dermatol; 2023 Aug; 22(8):835-837. PubMed ID: 37556529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phototherapy, psoriasis, and the age of biologics.
    Richard EG; Hönigsmann H
    Photodermatol Photoimmunol Photomed; 2014 Feb; 30(1):3-7. PubMed ID: 24313462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Phototherapy in the Age of Biologics.
    Calzavara-Pinton P; Zanca A; Arisi M; Rossi MT; Zane C; Venturini M; Ortel B
    Dermatology; 2018; 234(5-6):166-172. PubMed ID: 30205372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States.
    Armstrong AW; Koning JW; Rowse S; Tan H; Mamolo C; Kaur M
    Clin Drug Investig; 2017 May; 37(5):493-501. PubMed ID: 28303523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
    Zhang M; Carter C; Olson WH; Johnson MP; Brennem SK; Lee S; Farahi K
    J Drugs Dermatol; 2017 Mar; 16(3):220-226. PubMed ID: 28301617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.